Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-Biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy - Full Text View

Sponsored by:	Bristol-Myers Squibb
Information provided by:	Bristol-Myers Squibb
ClinicalTrials.gov Identifier:	NCT00124982

Purpose

The purpose of this study is to learn if Abatacept will provide clinical efficacy to subjects who have failed an anti-TNF therapy. The safety of this treatment will also be studied.

Condition	Intervention	Phase
Rheumatoid Arthritis	Drug: Abatacept	Phase III

MedlinePlus related topics: Rheumatoid Arthritis

Drug Information available for: Abatacept

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Official Title:	A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-Biologic DMARDs Who Have an Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:

Summarize the incidence of adverse events, serious adverse events and discontinuations due to adverse events based on physical exam findings, vital signs, laboratory test results and adverse events reported during the course of the study. [ Time Frame: at 6 months ]

Secondary Outcome Measures:

A disease activity score [ Time Frame: at 6 months and over time ]
Percentage of subjects achieving remission [ Time Frame: at 6 months ]
Discontinuation rate in subjects

Estimated Enrollment:	1000
Study Start Date:	April 2005
Study Completion Date:	January 2007

Arms	Assigned Interventions
A1: Experimental	Drug: Abatacept IV solution, IV infusion, between 500mg and 1gram based on body weight, monthly, 6 months.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Rheumatoid arthritis (RA) for greater than 1 year from the time of initial diagnosis.
American College of Rheumatology (ACR) functional class I, II, III
Subjects currently or previously received an anti-TNF therapy at an approved labeled dose for at least 3 months.

Exclusion Criteria:

Subjects with active vasculitis of a major organ system (except subcutaneous rheumatoid nodules).
History of cancer within the last 5 years (other than non-melanoma skin cell cancers cured by local resection).

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00124982

Show 157 Study Locations

Sponsors and Collaborators

Bristol-Myers Squibb

Investigators

Study Director:

Bristol-Myers Squibb

More Information

BMS Clinical Trials Disclosure This link exits the ClinicalTrials.gov site

For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm This link exits the ClinicalTrials.gov site

Publications indexed to this study:

Hassett AL, Li T, Buyske S, Savage SV, Gignac MA. The multi-faceted assessment of independence in patients with rheumatoid arthritis: preliminary validation from the ATTAIN study. Curr Med Res Opin. 2008 May;24(5):1443-53. Epub 2008 Apr 9.

Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougados M. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008 Apr;67(4):547-54. Epub 2007 Oct 5.

Study ID Numbers:	IM101-064
Study First Received:	June 30, 2005
Last Updated:	June 27, 2008
ClinicalTrials.gov Identifier:	NCT00124982
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Abatacept
Autoimmune Diseases
Musculoskeletal Diseases
Joint Diseases

Arthritis
Connective Tissue Diseases
Arthritis, Rheumatoid
Rheumatic Diseases

Additional relevant MeSH terms:

Immunologic Factors
Immune System Diseases
Therapeutic Uses
Physiological Effects of Drugs

Antirheumatic Agents
Immunosuppressive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009